Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Ashraf Eassa is a technology specialist with The Motley Fool. He writes mostly about technology stocks, but is especially interested in anything related to chips -- the semiconductor kind, that is.
Leigh Drogen is the Founder and CEO of Estimize. Estimize is an open financial estimates platform which facilitates the aggregation of fundamental estimates from independent, buy-side, and sell-side analysts, along with those of industry experts, private investors and students. By sourcing estimates from a diverse community of individuals, Estimize provides both a more accurate and more representative view of expectations compared to sell side only data.
Leigh started his career as a quant trader at Geller Capital, a White Plains, NY based fund where he ran strategies that looked at earnings acceleration and analyst estimate revision models, as well as price momentum and several sentiment indicators.
Leigh later went on to be the founder of Surfview Capital, a New York based asset management firm that used many of the same strategies as Geller Capital, with a focus on higher beta names on an intermediate term time frame.
His educational background includes focus in economics and international relations, specifically war theory. He is a graduate with honors from Hunter College in New York City.
You can contact Leigh by emailing him at Leigh@estimize.com
Author of the critically acclaimed book, "Taking Charge With Value Investing (McGraw-Hill, 2013)" and the premium subscription service "Tipping The Scale" (as seen below). An analyst that ranks in the top 4% on both tipranks.com and Motley Fool CAPS for stock picking performance.
Tipping the Scale members gain access to the TTS Portfolio Tracker. Here, members see what I am buying and selling the minute it happens, along with what I have owned, bought, and sold historically. These are just a few of the features on the TTS Portfolio Tracker.
Tipping The Scale is an equity research platform that uses a numeric scale instead of the traditional "Buy, Hold, Sell" to identify the best investment opportunities in the market. Stock coverage is determined by market catalyst, and every company goes through a vigorous test in 10 different categories. The higher the total score, the bigger the upside. In addition, Tipping the Scale also provides a number of portfolio strategies to hedge the volatility of the market and protect from downside.
Check out my instablog for more information on the popular research service Tipping the Scale, including performance information, benefits, and how it all works.
"Prediction is very difficult, especially if it's about the future." Nils Bohr
Leading pharmaceutical companies invest billions of dollars each year in research and development with little or no guarantee of a return on their investment.
With the average cost of developing a new drug hitting the $800 million mark, accurately forecasting the market potential for new compounds is becoming an essential tool in long-term strategic planning.
Forecasting is also essential in understanding how the dynamics of a market are changing, evaluating licensing and acquisition opportunities for a particular therapeutic candidate, and raising the awareness of company executives of both current and potential future competitors.
Last, but not least, pharmaceutical product forecasting provides precious building blocks for modeling and simulation exercises that investment analysts need to conduct on a continuous bases to estimate return-on-investment decisions and fine tune their portfolios.
Pharma Reports specializes in modeling and publishing short and medium term event-impacted linear forecasts for both new and established drugs.
Since actual brand performance depends on how the marketing company allocates its resources and how the competition responds to changes in market shares, we revise our forecasts periodically as new data points become available.
John Eastman is a writer, mixed media artist, and founder of several businesses (www.redfishcreative.com) (www.eastmantribe.com)with over 25 years of hands-on business and entrepreneurial experience. He currently works and resides in a studio loft in Pittsburgh, Pennsylvania and NYC. Mr. Eastman has exhibited and read in various galleries and exhibits in the region as an artist and writer.
Mr. Eastman is the co-founder of www.smallcapcity.com, an online publication that focuses on small capitalized public firms, founder of www.blackandwhiteprogram.com, an online publication offering interviews, essays, and reports. He also writes for www.thechairmansblog.com, www.smallcapcity.com, Motley Fool, and several other online and print publications.
Mr. Eastman’s business background commenced in 1985 with the launch of a series of high tech, real estate, and design firms. He has extensive experience in banking and loan servicing, real estate property management and asset management, asset appraisal and valuation, Office of Thrift Supervision (OTS) and FDIC bank closure proceedings.